Conference Brochure |Clinical Transplantation and Patient Care Conference

New COVID-19 nasal spray outperforms current antibody treatments in mice

2022-04-14 - 2022-04

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus' ability to enter cells. The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S. Food and Drug Administration (FDA). Notably, the top protein also neutralized all tested SARS-CoV-2 variants, something that many clinical antibodies have failed to do. When researchers administered the treatment to mice as a nasal spray, they found that the best of these antiviral proteins reduced symptoms of infection -- or even prevented infection outright. The findings were published yesterday (April 12) in the journal Science Translational Medicine.

Brochure Form

Abstracts enquiry

Registration enquiry

Contact Enquiry

Sponsors / Advertising

Phone

WhatsApp

Useful Links

News

New COVID-19 nasal spray outperforms current antibody treatments in mice

Newsletter